3-(4-methoxyphenyl)-6-methylisoquinolin-1-amine | 1029008-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(4-methoxyphenyl)-6-methylisoquinolin-1-amine
• CAS: 1029008-96-5
• 化学式: C₁₇H₁₆N₂O
• 分子量: 264.327
• InChiKey: GFZXOBFHLSOQID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methoxyphenyl)-6-methylisoquinolin-1-amine 在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 生成 3-(4-Methoxyphenyl)-6-methylisoquinolin-1-amine;hydrochloride
  参考文献：
  名称：

  Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents

  摘要：

  In the search for potent water-soluble 3-arylisoquinolines, several 3-arylisoquinolinamines were designed and synthesized. Various substituted 3-arylisoquinolinamines exhibited strong cytotoxic activity against eight different human cancer cell lines. In particular, C-6 or C-7 dimethylamino-substituted 3-arylisoquinolinamines displayed stronger potency than the lead compound 7a. Interestingly, compounds 7b and 7c showed more effective activity against paclitaxel-resistant HCT-15 human colorectal cancer cell lines when compared to the original cytotoxic cancer drug, paclitaxel. We analyzed the cell cycle dynamics by flow cytometry and found that treatment of human HCT-15 cells with 3-arylisoquinolinamine 7b blocked or delayed the progression of cells from G0/G1 phase into S phase, and induced cell death. Treatment with compound 7b also significantly inhibited the growth of tumors and enhanced tumor regression in a paclitaxel-resistant HCT-15 xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.132
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-(4-methoxyphenyl)-6-methylisoquinolin-1-amine
  参考文献：
  名称：

  Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents

  摘要：

  In the search for potent water-soluble 3-arylisoquinolines, several 3-arylisoquinolinamines were designed and synthesized. Various substituted 3-arylisoquinolinamines exhibited strong cytotoxic activity against eight different human cancer cell lines. In particular, C-6 or C-7 dimethylamino-substituted 3-arylisoquinolinamines displayed stronger potency than the lead compound 7a. Interestingly, compounds 7b and 7c showed more effective activity against paclitaxel-resistant HCT-15 human colorectal cancer cell lines when compared to the original cytotoxic cancer drug, paclitaxel. We analyzed the cell cycle dynamics by flow cytometry and found that treatment of human HCT-15 cells with 3-arylisoquinolinamine 7b blocked or delayed the progression of cells from G0/G1 phase into S phase, and induced cell death. Treatment with compound 7b also significantly inhibited the growth of tumors and enhanced tumor regression in a paclitaxel-resistant HCT-15 xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.132

文献信息

• 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof
  申请人：Lee Young B.

  公开号：US20080182871A1

  公开（公告）日：2008-07-31

  The present invention relates to 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives represented by general formula D, their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperproliferative disorders by administering the compounds are also included.

  本发明涉及一般公式D所代表的5,6或7-取代-3-(杂)芳基异喹啉胺衍生物及其药理学上可接受的盐，以及含有这类化合物的组合物。还包括通过给予这些化合物来治疗过度增殖性疾病的方法。
• 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF
  申请人：LEE YOUNG B.

  公开号：US20120029012A1

  公开（公告）日：2012-02-02

  The present invention relates to 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives represented by general formula D, their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperproliferative disorders by administering the compounds are also included.

  本发明涉及5、6或7-取代-3-(杂)芳基异喹啉胺衍生物D的一般式，其药理学上可接受的盐以及含有这种化合物的组合物。还包括通过给予这些化合物治疗过度增殖性疾病的方法。
• 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof
  申请人：Rexahn Pharmaceuticals, Inc.

  公开号：EP2423196A1

  公开（公告）日：2012-02-29

  The present invention relates to 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives represented by general formula D, their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperproliferative disorders by administering the compounds are also included.

  本发明涉及通式 D 所代表的 5、6 或 7-取代-3-(杂)芳基异喹啉胺衍生物、其药理学上可接受的盐，以及含有此类化合物的组合物。此外，还包括通过施用这些化合物来治疗过度增殖性疾病的方法。
• US8034829B2
  申请人：——

  公开号：US8034829B2

  公开（公告）日：2011-10-11
• US8314123B2
  申请人：——

  公开号：US8314123B2

  公开（公告）日：2012-11-20